These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25806091)

  • 21. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.
    Spunt SL; Freeman BB; Billups CA; McPherson V; Khan RB; Pratt CB; Stewart CF
    J Clin Oncol; 2007 Jun; 25(16):2274-80. PubMed ID: 17538173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin for the treatment of ovarian cancer.
    Bogliolo S; Cassani C; Gardella B; Musacchi V; Babilonti L; Venturini PL; Ferrero S; Spinillo A
    Expert Opin Investig Drugs; 2015; 24(9):1275-86. PubMed ID: 26125301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Singal R; Ramachandran K; Gordian E; Quintero C; Zhao W; Reis IM
    Clin Genitourin Cancer; 2015 Feb; 13(1):22-31. PubMed ID: 25178642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
    Oki Y; McLaughlin P; Pro B; Hagemeister FB; Bleyer A; Loyer E; Younes A
    Cancer; 2005 Aug; 104(4):781-7. PubMed ID: 15973667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
    Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
    Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
    Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
    Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
    Issa JP; Gharibyan V; Cortes J; Jelinek J; Morris G; Verstovsek S; Talpaz M; Garcia-Manero G; Kantarjian HM
    J Clin Oncol; 2005 Jun; 23(17):3948-56. PubMed ID: 15883410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
    Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer.
    Monnet I; Soulié P; de Cremoux H; Saltiel-Voisin S; Bekradda M; Saltiel JC; Brain E; Dupont-André G; Cvitkovic E
    J Clin Oncol; 2001 Jan; 19(2):458-63. PubMed ID: 11208839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
    Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
    BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
    Takimoto CH; Graham MA; Lockwood G; Ng CM; Goetz A; Greenslade D; Remick SC; Sharma S; Mani S; Ramanathan RK; Synold TW; Doroshow JH; Hamilton A; Mulkerin DL; Ivy P; Egorin MJ; Grem JL
    Clin Cancer Res; 2007 Aug; 13(16):4832-9. PubMed ID: 17699862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
    Locke F; Clark JI; Gajewski TF
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):509-14. PubMed ID: 19597729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
    Pendyala L; Creaven PJ
    Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.
    Piccart MJ; Green JA; Lacave AJ; Reed N; Vergote I; Benedetti-Panici P; Bonetti A; Kristeller-Tome V; Fernandez CM; Curran D; Van Glabbeke M; Lacombe D; Pinel MC; Pecorelli S
    J Clin Oncol; 2000 Mar; 18(6):1193-202. PubMed ID: 10715288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
    Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
    Ekblad L; Kjellström J; Johnsson A
    Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Severe Renal Dysfunction on the Plasma Levels of DNA-Reactive Platinum after Oxaliplatin Administration.
    Nakagawa S; Shimazaki A; Funakoshi T; Yonezawa A; Kataoka S; Horimatsu T; Hira D; Itohara K; Imai S; Nakagawa T; Matsubara T; Yanagita M; Muto M; Matsubara K; Terada T
    Biol Pharm Bull; 2023; 46(2):194-200. PubMed ID: 36724948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.